대한의생명과학회지 (Biomedical Science Letters)

  • 제27권4호
  • /
  • Pages.329-333
  • /
  • 2021
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

CD8-dependent Tumor Growth Inhibition by Tumor Cells Genetically Modified with 4-1BBL

  • Kim, Hong Sung (Department of Biomedical Laboratory Science, Korea Nazarene University)
  • 투고 : 2021.11.09
  • 심사 : 2021.11.22
  • 발행 : 2021.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We previously identified that tumor cells genetically modified with a 4-1BBL co-stimulatory molecule had anticancer effects in a CT26 mouse colorectal tumor model. To identify the distinction between immune cells in a mouse tumor model treated with tumor cells genetically modified with 4-1BBL or β-gal, we examined the immune cells in CT26-WT, CT26-βgal, and CT26-4-1BBL tumor bearing mice 21 days after tumor cell administration. The CD8+ T cells population in mice treated with tumor cells genetically modified with 4-1BBL was significantly increased on day 21 compared to that of tumor cells genetically modified with β-gal in the spleen and tumor tissue. The CD4+ T cell population was not different between the two mice groups. The Foxp3+CD25high CD4 T cell population decreased on day 21 in tumor tissues, but the decrease was not significant. We also found that CD8 T cells had pivotal roles in inhibiting tumor growth by treating mice with ant-CD4 and CD8 antibodies. These results suggest that tumor cells genetically modified with 4-1BBL could inhibit tumor growth by affecting on CD8 T lymphocytes.

키워드

과제정보

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education, Science and Technology (2010005446), and by Korea Nazarene University Research Fund.

참고문헌

  1. Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES, Shirwan H. A novel form of 4-1BBL prevents cancer development via nonspecific activation of CD4(+) T and natural killer cells. Cancer Research. 2019. 79: 783-794. https://doi.org/10.1158/0008-5472.can-18-2401
  2. Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor response in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cellular Immunology. 2001. 210: 56-65. https://doi.org/10.1006/cimm.2001.1804
  3. Habib-Agahi M, Jaberipour M, Searle PF. 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cellular Immunology. 2009. 256: 39-46. https://doi.org/10.1016/j.cellimm.2009.01.003
  4. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Research. 2009. 69: 8516-8525. https://doi.org/10.1158/0008-5472.CAN-09-2522
  5. Kim HS. Development of genetically modified tumor cell containing c0-stimulatory molecule. Biomedical Science Letters. 2019. 25: 398-406. https://doi.org/10.15616/BSL.2019.25.4.398
  6. Lee NK, Kim HS. Oncolytic vaccinia virus expressing 4-1BBL inhibits tumor growth by increasing CD8+ T cells in B16F10 tumor model. Biomedical Science Letters. 2012. 18: 210-217.
  7. Madireddi S, Schabowsky R-H, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventiolnal CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. PLoS One. 2012. 7: e42459. https://doi.org/10.1371/journal.pone.0042459
  8. Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. An engineered-4-1BBL fusion protein with "activity on demand". Proceedings of the National Academy of Sciences USA. 2020. 117: 31780-31788. https://doi.org/10.1073/pnas.2013615117
  9. Ragonnaud E, Andersson AM, Pedersen AE, Laursen H, Holst PJ. An adenoviral cancer vaccine co-endoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. Vaccine. 2016. 34: 2147-2156. https://doi.org/10.1016/j.vaccine.2015.06.087
  10. Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccine. Expert Review of Vaccines. 2014. 13: 387-398. https://doi.org/10.1586/14760584.2014.880340
  11. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine. 2007. 13: 1440-1449. https://doi.org/10.1038/nm1676
  12. Trub M, Uhlenbrock F, Claus C, Herzig P, Thelen M, Karanikas V, Bacac M, Amann M, Albrecht R, Ferrara-Koller C, Thommen D, Rothschield S, Savic Prince S, Mertz KD, Cathomas G, Rosenberg R, Heinzelmann-Schwarz V, Wiese M, Lardinosis D, Umana P, Klein C, Laubli H, Kashyap AS, Zippelius A. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. Journal for Immunotherpy of Cancer. 2020. 8: e000238. https://doi.org/10.1136/jitc-2019-000238
  13. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Molecular Cancer Therapeutics. 2012. 11: 1062-1070. https://doi.org/10.1158/1535-7163.MCT-11-0677
  14. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews. 2009. 229: 192-215. https://doi.org/10.1111/j.1600-065X.2009.00765.x
  15. Wang R, Freywald A, Chen Y, Xu J, Tan X, Xiang J. Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming CD44(+)CD62L(high)IL-7R(+) CTLs with up-and downregulation of anti- and pro-apoptosis genes. Cellular & Molecular Immnology. 2015. 12: 456-465. https://doi.org/10.1038/cmi.2014.72
  16. Yi KH, Nechushtan H, Bowers WJ, Walker GR, Zhang Y, Pham DG, Podack ER, Federoff HJ, Yolba KA, Rosenblatt JD. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Research. 2007. 67: 10027-10037. https://doi.org/10.1158/0008-5472.CAN-06-2391